Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Por Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M., Farago, Anna F., Wheler, Jennifer J., Liu, Stephen V., Doebele, Robert, Giannetta, Laura, Cerea, Giulio, Marrapese, Giovanna, Schirru, Michele, Amatu, Alessio, Bencardino, Katia, Palmeri, Laura, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Cresta, Sara, Damian, Silvia, Duca, Matteo, Ardini, Elena, Li, Gang, Christiansen, Jason, Kowalski, Karey, Johnson, Ann, Patel, Rupal, Luo, David, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S., Shaw, Alice T., De Braud, Filippo G.
Publicado no Cancer Discov (2017)